These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6539524)

  • 1. Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases.
    Eisenkraft S; Huben RP; Pontes JE
    Urology; 1984 Jun; 23(6 Suppl):51-3. PubMed ID: 6539524
    [No Abstract]   [Full Text] [Related]  

  • 2. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
    Tunn UW; Goldschmidt AJ; Peter K; Becker M
    Prog Clin Biol Res; 1990; 359():165-76; discussion 177-80. PubMed ID: 2149458
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
    Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
    Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy of advanced prostate cancer].
    Hofmann W; Langkopf B
    Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
    Rexer H
    Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
    Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy for hormone-refractory prostate cancer].
    Nishimura K; Takahara S; Nonomura N; Okuyama A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():266-71. PubMed ID: 12599583
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by roswell park memorial institute.
    Murphy GP; Slack NH; Mittelman A
    Urology; 1984 Jun; 23(6 Suppl):54-63. PubMed ID: 6375081
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade.
    Urakami S; Shiina H; Sumura M; Honda S; Wake K; Hiraoka T; Inoue S; Ishikawa N; Igawa M
    Int Urol Nephrol; 2008; 40(2):365-8. PubMed ID: 18092143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
    J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
    Hirayama Y; Ito Y; Kanamaru T; Sonoda T; Aoyama M; Nakamura N; Kawamura M
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):485-7. PubMed ID: 21403461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic agents effective in prostate cancer.
    Schmidt JD
    Semin Urol; 1983 Nov; 1(4):299-310. PubMed ID: 6399616
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
    Beckley S; Wajsman Z; Maeso E; Pontes E; Murphy G
    Urology; 1981 Dec; 18(6):592-5. PubMed ID: 7198328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.